Anti entity tumour medicinal composition containing plant alkaloid

A plant alkaloid and tumor drug technology, applied in the field of anti-solid tumor drug compositions, can solve the problems of effective drug concentration and limitation of local formation of difficult tumors

Inactive Publication Date: 2005-10-26
SHANDONG LANJIN PHARMA +1
View PDF8 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the excessive expansion and hyperplasia of solid tumors, the interstitial pressure, tissue elastic pressure, fluid pressure and interstitial viscosity are all higher than those of the surrounding normal tissues. Therefore, it is difficult for conventional chemotherapy to form an effective drug concentr

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0091] 80 mg of polyglycolic acid and glycolic acid copolymer (PLGA) with a molecular weight of 10000 are put into a container, add 100 milliliters of methylene chloride, after dissolving and mixing, add 10 mg of vincristine and 10 mg of cisplatin mitomycin C, Shake again and dry in vacuo to remove the organic solvent. The dried solid composition is shaped immediately, subpackaged and sterilized by radiation to obtain an anti-solid tumor pharmaceutical composition containing 10% vincristine and 10% cisplatin. All are percentages by weight. The drug release time of the anti-solid tumor pharmaceutical composition in physiological saline in vitro is 15-20 days, and the drug release time in mouse subcutaneous is 30-40 days.

Embodiment 2

[0093] The method step of being processed into the anti-solid tumor pharmaceutical composition is the same as in Example 1, but the difference is that the contained anti-cancer active ingredients are:

[0094] (A) 1-50% of vinblastine, isovinblastine, vinblastine, vinblastine, vinblastine, vincristine, podiazine, (sulfuric acid) vincristine, vinblastine, tartrate dehydration Vinblastine, Epoxy Vinblastine Tartrate, Epoxy Vinblastine, Vinblastine Tartrate, Hainan Crude Torresine, Hainan Crude Torrellactone, Vinpocetine, Vinorelbine, Bitartrate, Vinorelbine Ditartrate, Tartaric Acid Vinorelbine, vinblast, vinblast, vinpocetol, vinblast, vinblastine sulfate, vinblastine, vinblastine, vinblastine, vinblastine, vinblastine, vinblastine, vinblastine Ding, vinblastol, vinblastine, oxymatrine, harringtonine, deoxyharringtonine, homoharringtonine, pearl cyst shellin, monocrotaline, maytansine, erythrin, Camelides total alkaloids, heart chrysanthemum lactone, metansine, oridonin, Zhang...

Embodiment 3

[0098] Put 80 mg of polyglycolic acid and glycolic acid copolymer (PLGA) with a molecular weight of 20,000 into a container, add 100 ml of dichloromethane, dissolve and mix well, add 10 mg of vinblastine and 10 mg of mitozolomide, and re-shake Then dry in vacuo to remove the organic solvent. The dried solid composition is shaped immediately, subpackaged and then sterilized by radiation to prepare an anti-solid tumor pharmaceutical composition containing 10% vinblastine and 10% mitozolomide. All are percentages by weight. The drug release time of the anti-solid tumor pharmaceutical composition in physiological saline in vitro is 15-20 days, and the drug release time in mouse subcutaneous is 30-40 days.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A composite medicine for treating solid tumors by locally putting it in tumors is composed of the active anticancer component (plant alkaloid and its synergist chosen from Pt compounds, tetraazine medicines and topoenzyme depressant, and the medicinal auxiliary (biocompatible and biogradable high-molecular polymer).

Description

(1) Technical field [0001] The invention relates to an anti-solid tumor pharmaceutical composition containing plant alkaloids, which belongs to the technical field of medicines. (2) Background technology [0002] Cancer treatment mainly includes surgery, radiotherapy and chemotherapy. Among the various chemotherapeutic drugs used, plant alkaloids have obvious effects and have been widely used in various malignant tumors. However, after the single application of plant alkaloids, the DNA repair function in many tumor cells is significantly increased, so effectively reducing or inhibiting the DNA repair function in tumor cells has become the focus of current research. [0003] It has recently been found that inactivating or inhibiting intracellular DNA repair proteins can enhance the sensitivity of some tumor cells to chemotherapy, see Dolan et al. ""Cancer Research" 51 pp. 3367-3372 (1991) (Dolan et al., Cancer Res., 51, 3367-3372, 1991)). However, blood vessels, connective...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/00
Inventor 孔庆忠孙娟孔庆新孙忠厚
Owner SHANDONG LANJIN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap